Anzeige
Mehr »
Login
Samstag, 13.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Spezial: Montag letzte Chance vor großer Verkündung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PA4V | ISIN: CA58490H1073 | Ticker-Symbol:
NASDAQ
01.11.23
20:37 Uhr
0,161 US-Dollar
+0,004
+2,55 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDICENNA THERAPEUTICS CORP Chart 1 Jahr
5-Tage-Chart
MEDICENNA THERAPEUTICS CORP 5-Tage-Chart

Aktuelle News zur MEDICENNA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiMedicenna Therapeutics Corp.: Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer62100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H...
► Artikel lesen
DiMedicenna Therapeutics Corp: Medicenna presents MDNA11 clinical data at AACR1
DiMedicenna Therapeutics Corp: Medicenna presents preclinical data on MDNA113 at AACR1
DiMedicenna shares preclinical data on treatment targeting tumours1
DiMedicenna Therapeutics Corp.: Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)52MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the...
► Artikel lesen
04.04.Medicenna Therapeutics Corp. - 6-K, Report of foreign issuer1
04.04.Stocks in Play: Medicenna Therapeutics Corp-
06.03.Medicenna Therapeutics Corp. - 6-K, Report of foreign issuer1
06.03.Medicenna Therapeutics Corp.: Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting2
14.02.Medicenna Therapeutics Corp: Medicenna Therapeutics' Dec. 31 cash at $21.8 million1
14.02.Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update128With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint...
► Artikel lesen
13.02.Medicenna Therapeutics Corp: Medicenna doses first patient in combo Ability-1 study1
13.02.Medicenna Therapeutics Corp. - 6-K, Report of foreign issuer1
13.02.Medicenna Therapeutics Corp.: Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors168The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumorsMDNA11 continues...
► Artikel lesen
24.01.Medicenna Therapeutics Corp. - 6-K, Report of foreign issuer1
13.01.Medicenna Therapeutics Corp. - 6-K, Report of foreign issuer-
12.01.Medicenna Therapeutics Corp: Medicenna appoints MNP as auditor1
12.01.Medicenna Therapeutics Corp.: Medicenna Announces Appointment of New Auditor1
09.01.Medicenna Therapeutics Corp: Medicenna begins enrolment for Ability combo study2
09.01.Medicenna Therapeutics Corp.: Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab188The ABILITY-1 Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumorsMDNA11 continues...
► Artikel lesen
Seite:  Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1